Biosplice Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Biosplice Therapeutics's estimated annual revenue is currently $10.1M per year.
- Biosplice Therapeutics's estimated revenue per employee is $155,000
- Biosplice Therapeutics's total funding is $799M.
- Biosplice Therapeutics's current valuation is $12B.
Employee Data
- Biosplice Therapeutics has 65 Employees.
- Biosplice Therapeutics grew their employee count by -12% last year.
Biosplice Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | SVP Clinical Development and External Innovation | Reveal Email/Phone |
3 | VP, Deputy General Counsel | Reveal Email/Phone |
4 | VP, Biometrics | Reveal Email/Phone |
5 | VP Corporate Finance | Reveal Email/Phone |
6 | VP Discovery Research | Reveal Email/Phone |
7 | VP Clinical Operations | Reveal Email/Phone |
8 | SVP Clinical Development and External Innovation | Reveal Email/Phone |
9 | Executive Director, Portfolio & Programs Management | Reveal Email/Phone |
10 | Associate Director Clinical Data Management | Reveal Email/Phone |
Biosplice Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Biosplice Therapeutics?
$799M
Total Funding
65
Number of Employees
$10.1M
Revenue (est)
-12%
Employee Growth %
$12B
Valuation
N/A
Accelerator
Biosplice Therapeutics News
2022-04-20 - GV, Sanofi drive British biotech OMass to $100M series B ...
... Ventures have joined forces to pump $100 million into OMass Therapeutics, ... Biosplice: Once worth $12 billion, Biosplice laid off 41 workers in early...
2022-04-19 - 2 become 1: Caladrius and Cend merge into tumor-focused ...
That's how Caladrius Biosciences and Cend Therapeutics have described their ... Biosplice: Once worth $12 billion, Biosplice laid off 41 workers in early...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $12.3M | 65 | 5% | N/A |
#2 | $10.5M | 65 | 2% | N/A |
#3 | $14.7M | 65 | -11% | N/A |
#4 | $18M | 65 | -6% | N/A |
#5 | $10.1M | 65 | 0% | N/A |